Yabao Pharmaceutical Group Co., Ltd (SHA:600351)
China · Delayed Price · Currency is CNY 6.82
+0.12 (1.79%)
Sep 30, 2026, 3:00 PM CST
SHA:600351 Revenue
Yabao Pharmaceutical Group had revenue of 572.92M CNY in the quarter ending June 30, 2026, with 9.15% growth. This brings the company's revenue in the last twelve months to 2.25B, down -5.72% year-over-year. In the year 2025, Yabao Pharmaceutical Group had annual revenue of 2.24B, down -16.60%.
Revenue (ttm)
2.25B
Revenue Growth
-5.72%
P/S Ratio
2.10
Revenue / Employee
657.57K
Employees
3,415
Market Cap
4.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.24B | -445.97M | -16.60% |
| Dec 31, 2024 | 2.69B | -223.73M | -7.69% |
| Dec 31, 2023 | 2.91B | 191.63M | 7.05% |
| Dec 31, 2022 | 2.72B | -45.83M | -1.66% |
| Dec 31, 2021 | 2.76B | 161.54M | 6.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hunan Fangsheng Pharmaceutical | 1.87B |
| Fuan Pharmaceutical (Group) | 1.66B |
| Zhejiang AngLiKang Pharmaceutical CO.,LTD. | 1.33B |
| Hunan Hansen Pharmaceutical | 1.01B |
| Teyi Pharmaceutical Group Co.,Ltd | 826.71M |
| Zhongzhu Healthcare Holding Co.,Ltd | 533.88M |
| ChengDa Pharmaceuticals | 479.41M |
| Sinotherapeutics | 418.12M |